Even casual fans of Golf can easily see that the sport is enjoying widespread global popularity as well as very favorable demographic trends. These trends in the golf industry may help explain the ever-increasing popularity of the Golf Core Grip Workout System and mobile app sold by LifeApps Digital Media, Inc. (OTCQB – LFAP - $0.08 – Spec Buy).
|
Read more...
|
Based on preliminary figures, the new IOGA contract could be worth over $200M in revenue and nearly $50M in EBITDA to INSCOR over the next 3 years.
|
Read more...
|
Given the numerous upcoming corporate and developmental events, PLPL shareholders will be hugely rewarded as milestones are reached in 2H13.
|
Read more...
|
Considering the success of some of the programs in Israel in treating cancer patients with cannabis, Nuvilex Inc.’s (OTCQB – NVLX - $0.16 – Spec Buy) subsidiary, Medical Marijuana Sciences, Inc. may elect to emulate some of that country’s initiatives.
|
Read more...
|
The poor side effect profile for an already approved malaria drug serves as a major boost to Plandai Biotechnology Inc.’s (OTCQB – PLPL - $0.47 - Spec Buy) new malaria treatment efforts.
|
Read more...
|
By 2015 many industry analysts project that the majority of web traffic in the U.S. will be mobile-based, rather than computer-based web traffic. This shift plays directly into the sweet spot of LifeApps Digital Media, Inc
|
Read more...
|
Based on recent grants, , Nuvilex appears well positioned to be eligible to receive research lucrative grants or funding from other partner firms seeking to study the efficacy of live-cell encapsulation-based therapies used for oncology therapy, with medical marijuana.
|
Read more...
|
What better stock to own that one slated to double revenue for the year, record operating profit in the current quarter, with more revenue opportunities on the horizon in the fall.
|
Read more...
|
A 2007 study in the Journal of the American College of Nutrition looked at the effects of green tea catechins, specifically epigallocatechin gallate (EGCG), on subjects suffering from colds and flu. Over 32% fewer people in the green tea group experienced no cold and flu symptoms compared to the placebo group, and nearly 23% experienced less symptoms lasting fewer days. These results come as no surprise as EGCG and green tea catechins are found to be an inhibitor of common cold adenovirus.
|
Read more...
|
Recent events and future milestones serve to benefit Nuvilex as the stars align for management and its shareholders.
|
Read more...
|
|
|
<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>
|
Page 35 of 47 |